1 **Vitamin D status is associated with iron status, but not anemia, in African children**
2

Reagan M Mogire[1,2*], John Muthii Muriuki[1], Alireza Morovat[3], Alexander J Mentzer[4,5],
Emily L Webb[6], Wandia Kimita[1], Francis M Ndungu[1], Alex W Macharia[1], Clare L. Cutland[7],
Sodiomon B Sirima[8], Amidou Diarra[8], Alfred B Tiono[8], Swaib A Lule[6,9], Shabir A Madhi[10],
Andrew M. Prentice[11], Philip Bejon[1,12], John M Pettifor[13], Alison M Elliott[9,14], Adebowale
Adeyemo[15], Thomas N Williams[1,12,16] and Sarah H Atkinson[1,12,17*]

Authors' affiliations
[1]Centre for Geographic Medicine Research-Coast, KEMRI-Wellcome Trust Research
Programme, Kenya Medical Research Institute (KEMRI), Kilifi, Kenya.
[2]KEMRI-Wellcome Trust Research Programme - Accredited Research Centre, Open
University, Kilifi, Kenya.
[3]Department of Clinical Biochemistry, Oxford University Hospitals, Oxford, UK.
[4]Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of
Oxford, UK.
[5]Li Ka Shing Centre for Health Information and Discovery, Big Data Institute, University of
Oxford, Oxford, UK.
[6]Medical Research Council (MRC) International Statistics Epidemiology Group, Department
of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine,
London, UK.
[7]African Leadership in Vaccinology Expertise (Alive), Faculty of Health Sciences,
University of the Witwatersrand, Johannesburg, South Africa.
[8]Groupe de Recherche Action en Sante (GRAS), Ouagadougou 06, 06 BP 10248, Burkina
Faso.
[9]Medical Research Council/Uganda Virus Research Institute and London School of Hygiene
and Tropical Medicine Uganda Research Unit, Entebbe, Uganda.
[10]South African Medical Research Council Vaccines and Infectious Diseases Analytics
Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg,
South Africa.
[11]MRC Unit The Gambia at London School of Hygiene and Tropical Medicine, Banjul, The
Gambia
[12]Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine,
University of Oxford, Oxford, UK.
[13]South African Medical Research Council/Wits Developmental Pathways for Health
Research Unit, Department of Paediatrics, University of the Witwatersrand, Johannesburg,
South Africa.
[14]Department of Clinical Research, London School of Hygiene and Tropical Medicine,
London, UK.
[15]Centre for Research on Genomics and Global Health, National Human Genome Research
Institute, National Institutes of Health, South Drive, MSC 5635, Bethesda, Maryland 20891-
5635, USA.
[16]Department of Infectious Diseases and Institute of Global Health Innovation, Imperial
College, London, UK.

[17]Department of Paediatrics, University of Oxford, Oxford, UK.

Running title: Vitamin D and iron status in Africa

*Correspondence to:

Reagan M Mogire, Kenya Medical Research Institute (KEMRI), Centre for Geographic

Medicine, Coast, KEMRI-Wellcome Trust Research Programme, PO Box 230, Kilifi, Kenya,

e-mail: reaganmoseti@gmail.com Tel: +254 709 983274

Sarah H Atkinson, Kenya Medical Research Institute (KEMRI), Centre for Geographic

Medicine, Coast, KEMRI-Wellcome Trust Research Programme, PO Box 230, Kilifi, Kenya,

e-mail; satkinson@kemri-wellcome.org, phone number; +254 709 983000

Funding

This work was funded by Wellcome [grant numbers SHA 110255, TNW 202800, AJM
106289 and AME 064693, 079110, 095778], and with core awards to the KEMRI-Wellcome
Trust Research Programme [203077]. AA is supported by the Intramural Research Program
of the National Institutes of Health in the Center for Research on Genomics and Global
Health (CRGGH). The CRGGH (1ZIAHG200362) is supported by the National Human
Genome Research Institute, the National Institute of Diabetes and Digestive and Kidney
Diseases, the Center for Information Technology, and the Office of the Director at the
National Institutes of Health. RMM is supported through the Developing Excellence in
Leadership, Training and Science (DELTAS) Africa Initiative [DEL-15-003]. The DELTAS
Africa Initiative is an independent funding scheme of the African Academy of Sciences
(AAS)'s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by
the New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD
Agency) with funding from Wellcome [107769] and the UK government. The Gambian work
was supported by the UK MRC (U1232661351, U105960371 and MC-A760-5QX00) and
DFID under the MRC/DFID Concordat. The views expressed in this publication are those of
the authors and not necessarily those of AAS, NEPAD Agency, Wellcome or the UK
government. For the purpose of Open Access, the authors have applied a CC-BY public
copyright licence to any author accepted manuscript version arising from this submission.

The funders had no role in the study design, data collection, data analysis, data interpretation,

or writing of the report.

Conflicts of Interest

The authors report no conflicts of interest.

Abbreviations used: 1,25(OH)$_2$D, 1,25-dihydroxyvitamin D; 25(OH)D, 25-hydroxyvitamin

D; ACT, α1-antichymotrypsin; CRP, C-reactive protein; DEQAS, Vitamin D External

Quality Assessment Scheme; FGF23, fibroblast growth factor 23; *HAMP,* hepcidin gene; ID,

iron deficiency; IDA, iron deficiency anemia; IL6, interleukin 6; IL1B, interleukin 1 beta;

IQR, interquartile range; JAK-STAT3, Janus kinase-signal transducer and activator of

transcription 3; RCT, randomized clinical trial; sTfR, soluble transferrin receptor; TSAT,

transferrin saturation; VDRE, vitamin D response element.

90
91

Abstract

Background

Nutritional deficiencies, including vitamin D and iron deficiency, are prevalent among

children living in sub-Saharan Africa. Vitamin D inhibits the transcription of the iron

hormone hepcidin thus permitting efficient iron absorption, and iron deficiency alters vitamin

D metabolism. Studies have reported associations between vitamin D and iron status, but

little is known about their association in African populations.

Objective

We aimed to evaluate the association between vitamin D and iron status in African children.

Methods

In this cross-sectional study, we measured biomarkers of iron status, inflammation and 25-

hydroxyvitamin D (25(OH)D) levels in 4509 children aged 0.3 months to 8 years from

Kenya, Uganda, Burkina Faso, The Gambia and South Africa. We used regression analyses

to evaluate the association between vitamin D and iron status.

Results

Stunting, underweight, inflammation and malaria were highly prevalent. Overall prevalence

of iron deficiency was 35.1%, while the prevalence of vitamin D deficiency was 0.6% and

7.8% as defined by 25(OH)D levels of <30 nmol/L and <50 nmol/L respectively. Children

with 25(OH)D levels <50 nmol/L had an 80% increased risk of iron deficiency (OR 1.80

[95% CI 1.40, 2.31]) and had lower hepcidin levels than those with 25(OH)D levels >75

nmol/L. 25(OH)D levels were positively associated with ferritin, hepcidin and soluble

transferrin receptor levels and negatively associated with serum iron and transferrin

saturation in multivariable regression analyses. Vitamin D status was not associated with

hemoglobin levels or anemia.

Conclusions

These findings suggest that vitamin D deficiency may variably influence different iron

compartments and measures of iron status in young African children. Additional research is

required to confirm these findings and determine direction of causality. The interplay

between vitamin D and iron status should be considered in strategies to manage these nutrient

deficiencies in African populations.

Keywords

Vitamin D deficiency, iron deficiency, hepcidin, ferritin, soluble transferrin receptor,

hemoglobin, serum iron, transferrin saturation, anemia, children, Africa.

Introduction

Vitamin D and iron deficiency are two of the most common nutrient deficiencies worldwide (1, 2). Approximately 23% and 52% of children living in Africa are estimated to have vitamin D and iron deficiency, respectively (3, 4). Vitamin D deficiency has been linked to rickets and many infectious diseases (1) while iron deficiency is a major cause of anemia, impaired development and disability in children (2, 5).

Previous *in vitro* and animal studies point to a complex interplay between vitamin D and iron metabolism (illustrated in Figure 1). Higher vitamin D status may improve iron status by decreasing levels of hepcidin, the principal iron-regulatory hormone, through the binding of the 1,25-dihydroxyvitamin D (1,25(OH)$_2$D)–vitamin D receptor complex to the vitamin D response element (VDRE) on the hepcidin gene (*HAMP*) thus inhibiting its transcription (6), and by suppressing pro-inflammatory cytokines (IL6 and IL1B) (7), thus allowing iron absorption. Conversely, iron deficiency may also cause vitamin D deficiency by decreasing the activity of heme-containing vitamin D-activating enzymes such as 25- and 1α-hydroxylase, as demonstrated in rats (8), or by increasing fibroblast growth factor 23 (FGF23) (9, 10), which suppreses the 1α-hydroxylation of vitamin D (11, 12). However, observational studies and clinical trials have reported mixed findings, and there are few studies in Africa or in young children. A study in African preschool children (n = 500) showed that 25-hydroxyvitamin (25(OH)D) levels were positively correlated with hemoglobin levels in a subgroup of Maasai children (13) and pregnant women supplemented with iron had lower 25(OH)D levels than those receiving placebo, although levels did not differ in cord blood (10). Studies in young, hospital-attending Indian and South Korean children (n = 263 and n = 102, respectively) reported mixed findings, as have nationally

representative surveys in older age groups in South Korea (n = 2526), the USA (n = 5456)

and Germany (n = 5066) (14-18).

The aim of the current study was to investigate the associations between vitamin D status,

iron deficiency, and anemia in 4509 young children living in countries across the African

continent.

Methods

Study population

This study included cross-sectional data from young children living in Kenya, Uganda,

Burkina Faso, The Gambia and South Africa, as described below.

Kilifi, Kenya (0.3 months–8 years): This is an ongoing community-based cohort aimed at

evaluating immunity to malaria in children living in Kilifi, Kenya (19). Children are followed

up from birth up to a maximum of 13 years with annual cross-sectional bleeds and weekly

monitoring for malaria. 25-hydroxyvitamin D (25(OH)D), iron and inflammatory biomarkers,

anthropometry, and malaria parasitemia were measured from a single cross-sectional bleed

based on the availability of plasma samples archived at -80°C.

Entebbe, Uganda (1–5 years): The Entebbe Mother and Baby Study (EMaBS) is a

prospective birth cohort study that was designed as a randomized controlled trial aimed at

evaluating the effects of helminths and anthelmintic treatment on immunological and disease

outcomes (20). Blood samples were collected at birth and at subsequent birthdays up to five

years of age. 25-hydroxyvitamin D (25(OH)D), iron and inflammatory biomarkers,

anthropometry, and malaria parasitemia were measured from a single annual visit based on

the availability of stored samples.

Banfora, Burkina Faso (6 months–2.5 years): The VAC050 ME-TRAP Malaria Vaccine

Trial was a clinical trial aimed at testing the effectiveness, safety and immunogenicity of a

malaria vaccine in infants aged between six and 17 months (21). 25-hydroxyvitamin D

(25(OH)D), iron and inflammatory biomarkers, anthropometry, and malaria parasitemia were

measured at a single time point.

West Kiang, The Gambia (2–6 years): This study included children aged between two and six

years recruited from rural villages in the West Kiang district in The Gambia prior to the

malaria season as previously described (22). Biomarkers, anthropometry and malaria

parasitemia were measured during a single cross-sectional survey.

Soweto, South Africa (4 months–2.8 years): The Soweto Vaccine Response Study comprised

of children who were participating in clinical vaccine trials. Samples for the current study

were obtained from infants aged around 12 months. This cohort was not exposed to malaria

and did not have anthropometric or hemoglobin measurements (23).

Laboratory assays

25(OH)D levels, iron and inflammatory biomarkers were assayed as previously described (4,

24) and are summarized in Supplementary Methods 1. The assays showed satisfactory

performances as monitored by both external quality assurance schemes (including UK

National External Quality Assessment Scheme and DEQAS) and 4-hourly internal quality

control assessments. Overall coefficient of variation for 25(OH)D measurements ranged from

2.8% to 7.9%. Over the duration of analyses, three sets of external quality assurance

(DEQAS) data showed the 25(OH)D assay to have a mean (SD) bias of -2.7% (7.6) against

the all-laboratory trended 25(OH)D values, and one of -0.4% (7.7) against the target values.

Malaria parasitaemia was detected by blood film microscopy using the Giemsa staining

technique.

Definitions

Vitamin D status was defined using 25(OH)D cutoffs of <30 nmol/L, <50 nmol/L and 50–75

nmol/L (25, 26). Inflammation was defined as CRP levels >5 mg/L or ACT >0.6 g/L (27).

Iron deficiency was defined using WHO guidelines as plasma ferritin <12µg/L or <30µg/L in

the presence of inflammation in children <5 years old, and as <15µg/L or <70µg/L in the

presence of inflammation in children ≥5 years old (28). Transferrin saturation (TSAT) was

calculated as (serum iron in µmol/L/transferrin in g/L x 25.1) x 100 (29). Anemia was

defined as hemoglobin <11 g/dL in children aged <5 years, or hemoglobin <11.5 g/dL in

children ≥5 years and iron deficiency anemia as the presence of both iron deficiency and

anemia (30). Malaria parasitaemia was defined as the presence of *Plasmodium* parasites in

blood. Stunting was defined as height-for-age z-scores (HAZ) <-2 and underweight as

weight-for-age (WAZ) <-2 according to 2006 WHO child growth standards (31).

Statistical analyses

Statistical analyses were conducted using STATA 15.0 (StataCorp., College Station, TX). All

biomarkers except transferrin and hemoglobin were natural log-transformed to normalize

their distribution for regression analyses. Logistic and linear regression analyses were

performed to evaluate the associations between vitamin D status (ln-25(OH)D levels and

25(OH)D levels of <50, between 50–75, and >75 nmol/L) and iron deficiency, anemia and

individual markers of iron status, where appropriate. Multivariable models were adjusted for

study site, age, sex, season and inflammation. Regression models inlcuded only obervations

with values for all the variables inlcuded in the model. Since inflammation alters markers of

iron status, we stratified by inflammation in secondary multivariable regression analyses and

tested for interactions between inflammation and 25(OH)D levels in predicting individual

markers of iron status.

Results

Characteristics of study participants

The study included 1361 Kenyan, 1301 Ugandan, 329 Burkinabe, 629 Gambian and 889

South African children. The characteristics of study participants are presented in Table 1. The

children had a median age of 23.9 months (IQR 12.3, 35.9) and 49.1% were girls. Prevalence

of stunting, underweight, inflammation and malaria parasitemia were high and varied by

country. Overall median 25(OH)D levels were 77.0 (95% CI 76.3, 77.7) nmol/L. Prevalence

of vitamin D deficiency was 0.6% and 7.8% using 25(OH)D cutoffs of <30 nmol/L and <50

nmol/L respectively, while 35.4% of children had levels between 50–75 nmol/L. Since few

children had 25(OH)D levels <30 nmol/L, the <50 nmol/L cutoff was used for further

analyses. Prevalence of iron deficiency, iron deficiency anemia and anemia was 35.1%,

23.0% and 61.6%, respectively. South African children had the highest prevalence of low

vitamin D status (25(OH)D <50 nmol/L) and iron deficiency at 13.5% and 42.0%,

respectively.

Vitamin D status is associated with iron status

The prevalence of iron deficiency was higher in children with 25(OH)D levels of <50 nmol/L

(41.8%; 95% CI 36.7, 47.1) compared to those with levels >75 nmol/L (35.8% [95% CI 33.9.

37.2]). Similarly, the prevalence of vitamin D deficiency was higher in iron deficient children

(9.3% [95% CI 7.9, 10.8] compared to those who were iron replete (7.0% (95% CI 6.1, 8.0])

(Supplementary Figure 1). In overall multivariable logistic regression analyses, 25(OH)D

levels <50 nmol/L increased the odds of iron deficiency by 80% (OR 1.80 [95% CI 1.40,

2.31]) compared to 25(OH)D levels >75 nmol/L although associations varied by country.

25(OH)D levels <50 nmol/L showed limited evidence of association with risk of IDA (OR

1.41 [95% CI 0.97, 2.07]) (Table 2). Ferritin levels were similarly lower in children with

25(OH)D levels <50 nmol/L (15.2 µg/L [95% CI 13.4, 17.2]) compared to those with

25(OH)D levels >75 nmol/L (20.5 µg/L [19.6, 21.3]) (Supplementary Table 2).

Children with 25(OH)D levels <50 nmol/L had lower hepcidin levels (5.3 µg/L (95% CI 4.6,

6.1) compared to those with 25(OH)D levels >75 nmol/L (6.4 µg/L (95% CI 6.1, 6.6)

(adusted beta -0.30 [95% CI -0.45, -0.16], p <0.0001) in keeping with iron deficiency.

However, sTfR, and transferrin levels were lower, and serum iron and TSAT levels were

higher, in children with 25(OH)D levels <50 nmol/L compared to those with 25(OH)D levels

>75 nmol/L in unadjusted (Figure 2), and adjusted models (Supplementary Table 2)

suggesting improved iron status. 25(OH)D levels were highly correlated with all of the iron

markers except hepcidin (Supplementary Figure 2) and in linear regression analyses

controlling for age, sex, season, inflammation and study site, 25(OH)D levels were positively

associated with ferritin, hepcidin, sTfR, and transferrin levels, and negatively associated with

serum iron concentrations and TSAT (Figure 3).

CRP levels also differed by vitamin D status and were lowest in children with 25(OH)D

levels <50 nmol/L, higher in those with levels between 50–75 nmol/ and highest in those with

levels >75 nmol/L (Figure 2 H). Since inflammation alters measures of iron status and also

differs by vitamin D status, we further stratified by the presence of inflammation and looked

for interactions between inflammation and 25(OH)D levels in predicting iron status. We

observed that 25(OH)D levels remained highly associated with measures of iron status in the

absence of inflammation in multivariable linear regression analyses (Figure 3). We also

found an interaction between inflammation and 25(OH)D levels in predicting ferritin levels,

so that in children with inflammation a unit change in 25(OH)D levels was associated with a

smaller unit change in ferritin levels than in children without inflammation (Supplementary

Table 3).

Vitamin D status is not associated with hemoglobin levels or anemia

Hemoglobin levels did not differ by vitamin D status (Figure 2). Similarly, low vitamin D

status (25(OH)D levels <50 nmol/L) was not associated with anemia in overall multivariable

logistic regression analyses or in individual study sites, except in The Gambia where it was

associated with higher odds of anemia (OR 2.75 [95% CI 1.45, 5.17]) compared to 25(OH)D

levels >75 nmol/L (Table 2). Hemoglobin levels were similarly not associated with 25(OH)D

levels in multivariable regression analyses (Figure 3).

Discussion

Nutritional deficiencies, including iron deficiency, are highly prevalent among young

children living in Africa and may alter the metabolism of other nutrients. In the current study,

low vitamin D status (defined here as 25(OH)D levels <50 nmol/L) was associated with an

80% increased risk of iron deficiency and iron deficient children similarly had a higher

prevalence of low vitamin D status. Low vitamin D status was associated with reduced levels

of ferritin and hepcidin in keeping with increased iron deficiency, but was also associated

with reduced sTfR and transferrin levels and increased TSAT and serum iron levels

suggesting improved iron status in these iron compartments. These associations were

observed after adjusting for inflammation in multivariable models and in the absence of

inflammation. We found limited evidence of increased risk of iron deficiency anemia in

vitamin D deficient children, and no evidence of association between vitamin D status and

anemia or hemoglobin levels.

Low vitamin D status was associated with increased risk of iron deficiency and low ferritin

levels in young African children in this study. This finding varied by country, with the

strongest association observed in South African children. These findings are consistent with a

nationally representative survey of 2526 children and young adults aged between 10 to 20

years from South Korea, which showed that vitamin D deficiency (25(OH)D levels <37.5

nmol/L) was associated with a 94% increased odds of iron deficiency (OR 1.94 [95% CI,

1.27–2.97]) (15). Vitamin D deficiency was also associated with increased risk of iron

deficiency in a national survey of women in South Korea (n=10,169) (32), female athletes in

Poland (n=219) (33) and pregnant women in Indonesia (n=203) (34). However, four other

observational studies including a national survey of 5066 German adolescents (aged from 11

to 17 years) found no association between vitamin D status and ferritin levels (Supplementary

Table 4). Vitamin D supplementation also had no effect on ferritin levels in 14 out of 15

clinical trials (Supplementary Table 5). We found that 25(OH)D levels more strongly

influenced ferritin and other iron measures in the absence of inflammation, suggesting that

inflammation may attenuate the effect of vitamin D status on these markers of iron status,

perhaps explaining the stronger association observed in South African children. We observed

limited evidence of association between low vitamin D status and increased odds of iron

deficiency anemia. In contrast, five studies have reported a positive association between

vitamin D deficiency and iron deficiency anemia (Supplementary Table 4), although the

causes of anaemia in African children are likely to be different from those in these studies.

In the current study, 25(OH)D levels were inversely associated with hepcidin levels in

multivariable models and hepcidin levels were lower in children with low vitamin D status

compared to those with 25(OH)D levels >75 nmol/L. In agreement, Japanese patients with

rheumatoid arthritis with 25(OH)D levels <75 nmol/L had lower hepcidin levels than those

with 25(OH)D levels >75 nmol/L (35), although another study in patients with inflammatory

bowel disease found higher hepcidin levels (n=69), and no association was observed in

healthy Mexican adults (n=783) (Supplementary Table 4) (36). In contrast to our study, four

out of nine clinical trials conducted in the USA and Japan, including two in healthy adults,

reported that vitamin D supplementation (with doses ranging from 3000 – 250,000 IU per

day) decreased hepcidin levels, while five other trials (with doses ranging from 1000 IU to

10,000 per day) did not report any effects (Supplementary Table 5). *In vitro* and animal

studies indicate that vitamin D can decrease hepcidin levels by either directly inhibiting

transcription of the hepcidin gene (HAMP), suppressing the production of pro-inflammatory

cytokines IL-6 and IL-1B, or by activating the JAK-STAT3 pathway (Figure 1) (6, 7, 37).

The converse finding of lower hepcidin levels in vitamin D deficient children in our study is

likely due to the increased prevalence of iron deficiency in the vitamin D deficient children

since iron deficiency is known to exert a powerful inhibitory effect on hepcidin expression in

African children (38).

Low vitamin D status was however associated with improved iron status for other markers of

iron status, that is, increased serum iron and TSAT and decreased transferrin and sTfR levels

compared to 25(OH)D levels >75 nmol/L. A single study investigating the association

between TSAT and 25(OH)D levels observed that higher 25(OH)D levels were associated

with increased TSAT in healthy adolescent Saudi boys, although not in girls or in pooled

analyses (39). A clinical trial of 125 Saudi children also reported that 1000 IU of vitamin D

supplement per day decreased TSAT (40), although five other trials observed no effect

(Supplementary Table 5). In contrast to our study, seven observational studies reported no

association between vitamin D status and serum iron levels and two found that low vitamin D

status was associated with reduced serum iron levels (Supplementary Table 4). Clinical trials

of the effect of vitamin D supplementation have reported mixed associations with one trial

reporting decreased and one increased serum iron levels in the treatment group, and others no

association (Supplementary Table 5). In contrast to our study, vitamin D deficiency was

associated with increased sTfR levels in two observational studies involving children and

adolescents in Germany (16) and in Polish athletes (33). However, vitamin D

supplementation had no effect on sTfR or transferrin levels in three clinical trials

(Supplementary Table 5). There may be a few explanations for the higher serum iron and

TSAT and lower sTfR levels observed in vitamin D deficient children in the current study. It

is possible that the lower hepcidin levels observed in vitamin D deficient children may have

led to increased iron absorption (41) resulting in higher serum iron levels and TSAT and

higher vitamin D status has been suggested to promote erythropoiesis (42) which may explain

lower sTfR levels in vitamin D deficient children.

In the current study, low vitamin D status was not associated with hemoglobin levels or

anemia. In agreement with our study, two studies involving healthy children from China (n =

1218, aged 0.5 – 14 years) and Jordan (n= 203, aged 0.5 – 3 years) did not find an association

between vitamin D status and hemoglobin levels or anemia, although other observational

studies (18 out of 22), including one in school going children aged between 3–5 years in

Kenya, reported a positive association (Supplementary Table 4). A systematic review and

meta-analysis of seven observational studies with 5183 participants showed that vitamin D

deficiency was associated with 84% higher odds of anemia (OR 2.25, 95% CI 1.47-3.44)

(43). Clinical trials that investigated the effect of vitamin D interventions on hemoglobin

levels or anemia status have also reported mixed findings with many studies showing no

effect (Supplementary Table 5). Hemoglobin levels are influenced by many factors, including

malaria, undernutrition and sickle cell disease, in African children and this may explain why

we did not observe an association between vitamin D status and anemia in our study.

Conversely, iron status is also likely to have influenced vitamin D status and we observed a

higher prevalence of low vitamin D status in children with iron deficiency. Since our study

was observational we were unable to ascertain the direction of causality between vitamin D

and iron status. Iron deficiency may lead to vitamin D deficiency via a number of pathways

including by reducing the activity of heme-containing vitamin D metabolizing enzymes such

as 25-hydroxylase and 1-alpha-hydroxylase (8) or by reducing vitamin D absorption in the

gastrointestinal tract through impairing epithelial function (44) (Figure 1). Iron deficiency has

also been shown to increase levels of fibroblast growth factor 23 (FGF23) levels (9, 10)

which suppresses 1 α-hydroxylase activity (11, 12). Heldenberg and colleagues have also

reported that intramuscular administration of iron dextran or iron-fortified formula milk in 25

infants with iron deficiency anemia resulted in increased 25(OH)D levels, although no

placebo group was included (45). In contrast, pregnant Kenyan women (n = 433)

supplemented with iron from 13–23 weeks of gestation until 1 month postpartum had lower

25(OH)D levels than those who received a placebo, although no differences were observed in

cord blood (10). In addition, another study found no effects of iron fortified juice on

25(OH)D levels in 41 iron deficient women (46).

Our study had a number of strengths. To the best of our knowledge, this is the first study to

investigate the association between vitamin D status and iron deficiency in African children.

Children living in sub-Saharan Africa have a high burden of iron deficiency, undernutrition

and infectious diseases, which might explain why some of our findings differed from studies

in European populations. Additionally, we included a large number of healthy children (n =

4509) living in five different countries across Africa. We also measured a wide range of iron

biomarkers which enabled us to evaluate how vitamin D status is associated with various

aspects of iron status. However, our study had some limitations. First, the study was cross-

sectional, hence we could not evaluate temporal changes in the observed associations or

determine the direction of causality and there may have been other unmeasured confounders

that influenced our findings. Secondly, we only included young children in our study which

may limit the generalizability of our findings to other age groups. Our findings also varied by

country, which may be because different factors influence iron and vitamin D status across

the African continent. We also did not collect information that may have influenced vitamin

D or iron status such as dietary intake, sunlight exposure or hookworm infections.

In conclusion, our findings suggest that vitamin D status is linked with iron status in young

African children, with the direction of association varying depending on the iron status

marker. Low vitamin D status was associated with iron deficiency as indicated by reduced

ferritin and hepcidin levels, although reduced sTfR and increased serum iron and TSAT

suggests that these children may be more iron replete. There is a need for further studies to

understand the associations between vitamin D and iron deficiency and determine causality

and putative mechanisms of action in African populations.

Acknowledgements: The authors would like to thank the teams at the KEMRI-Wellcome

Trust Research Programme in Kenya, UVRI/MRC Entebbe Mother and Baby Study in

Uganda, the Malaria Vectored Vaccines Consortium (MVVC) in Burkina Faso, the

Respiratory and Meningeal Pathogens Unit (RMPRU) in South Africa, and the MRC Unit

The Gambia at London School of Hygiene and Tropical Medicine in The Gambia. In

addition, the authors wish to specifically express their grattitide to Jedidah Mwacharo and

Barnes Kitsao at the KEMRI-Wellcome Trust Research Programme for assisting in sample

retrieval.

Ethics approval and consent to participate

Informed written consent was obtained from all children's parents or guardians before

inclusion in the study. Ethical approvals were granted by the Scientific Ethics Review Unit of

the Kenya Medical Research Institute (KEMRI/SERU/CGMR-C/046/3257) in Kenya, the

Uganda Virus Research Institute (GC/127/12/07/32) and Uganda National Council for

Science and Technology (MV625) in Uganda, by Ministere de la Recherche Scientifique et

de l'Innovation (reference 2014-12-151) in Burkina Faso, the Gambian Government and the

Medical Research Council Ethics Review Committee in The Gambia (874/830), the

University of Witwatersrand Human Research Ethics Committee (M130714) in South Africa

and in the UK by the London School of Hygiene and Tropical Medicine (A340) and the

Oxford Tropical Research Ethics Committees (39-12, 41-12, 42-14, and 1042-13).

Authorship contributions

RMM, JMM, AA, TNW and SHA conceived and designed the study. Data was obtained by

all the authors and analysed by RMM, JMM, and SHA. RMM and SHA wrote the first draft

of the manuscript. RMM, JMM, AJM, EMW, WK, AWM, FMN, CC, SBS, AD, ABT, SAL,

AM, SAM, AMP, PB, JMP, AME, AA , TNW, SHA contributed to data interpretation,

reviewed successive drafts and approved the final version of the manuscript. The sponsors

played no role in the study design, data collection, data analysis, data interpretation or writing

of the report.

Conflict of Interest Disclosures

Authors declare no conflict of interest.

Data availability

The data and analyses scripts underlying this article are available in Harvard Dataverse at

https://doi.org/10.7910/DVN/A78P8B and applications for data access can be made through

the Kilifi Data Governance Committee cgmrc@kemri-wellcome.org.

Figure legends

Figure 1. Metabolism of vitamin D and iron is interlinked. 1,25(OH)2D may influence
iron status by reducing hepcidin levels through directly binding to the vitamin D response
element (VDRE) in the promoter region of the hepcidin gene (*HAMP*), decreasing pro-
inflammatory cytokines (e.g. IL6, IL1B) and supporting erythropoiesis (6, 7, 37, 47). Low
iron status may also influence vitamin D status by decreasing the activity of vitamin D
metabolising enzymes (25- and 1α-hydroxylase) (8) and increasing FGF23 (48). High levels
of FGF23 suppress 1α-hydroxylase activity thus reducing 1,25(OH)2D levels (14, 16).
Abbreviations: sTfR, soluble transferrin receptor; DMT1, divalent metal transporter 1; DBP
vitamin D binding protein; Cp, ceruloplasmin; FGF23, fibroblast growth factor 23; RBC, red
blood cell; 7-DHC, 7-dehydrocholesterol.

Figure 2. Boxplot of iron markers and CRP levels by vitamin D status categories.
Children with 25(OH)D levels <50 nmol/L had lower levels of ferritin (A), hepcidin (B),
sTfR (C), transferrin (D), and higher serum iron levels (E) and TSAT (F) compared to
children with 25(OH)D levels >75nmol/L. CRP levels (H) were lower in the group with
25(OH)D levels <50 nmol/L. P values were obtained from two-sample Wilcoxon rank-sum
(Mann-Whitney) test. Median (IQR) values and associated p values are presented in
Supplementary Table 2. Abbreviations: TSAT, transferrin saturation; sTfR, soluble
transferrin receptor. Test of signficance p value; not significant (ns) > 0.05; * <0.05, **
<0.01, *** 0.001.

**Figure 3. Effect of 25(OH)D levels on iron markers overall (dark grey) and in children
with and without inflammation (black and light grey lines respectively).** Both the
dependent and independent variables (except transferrin and hemoglobin) were log-
transformed before inclusion in the linear model. Thus the beta values may be interpreted as
follows: a 1% change in 25(OH)D levels corresponds to a beta % change in the individual
iron markers. All models were adjusted for age, sex, season, and study site and the overall
model was additionally adjusted for inflammation. Inflammation was defined as CRP > 5
mg/L or ACT >0.6 g/L (ACT, but not CRP was available for The Gambia). Error bars
indicate 95% confidence intervals. Abbreviations: TSAT, transferrin saturation; sTfR, soluble
transferrin receptor.
465

Supplementary Figure 1. Prevalence of iron status by vitamin D status categories (i) and
prevalence of vitamin D status by iron status categories (ii). Iron deficiency was defined
as plasma ferritin <12µg/L or <30µg/L in the presence of inflammation in children <5 years
old, or <15µg/L or <70µg/L in the presence of inflammation in children ≥5 years old.
Inflammation was defined as CRP > 5 mg/L or ACT >0.6 g/L (ACT, but not CRP was
available for The Gambia). A chi-squared test (*prtest)* was used to test the significance in
difference in proportion of low vitamin status (25(OH)D levels <50 or 50–75 nmol/L) within
each category with the first category as the reference.
474
475 **Supplementary Figure 2. Scatter and regression plots of markers of iron status and C-**
476 **reactive protein against log 25(OH)D levels.** Abbreviations: TSAT, transferrin saturation;
477 sTfR, soluble transferrin receptor; CRP, C-reactive protein.
478
479

References

1. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357(3):266-81. doi: 10.1056/NEJMra070553.
2. Kassebaum NJ. The Global Burden of Anemia. Hematol Oncol Clin North Am 2016;30(2):247-308. doi: 10.1016/j.hoc.2015.11.002.
3. Mogire RM, Mutua A, Kimita W, Kamau A, Bejon P, Pettifor JM, Adeyemo A, Williams TN, Atkinson SH. Prevalence of vitamin D deficiency in Africa: a systematic review and meta-analysis. Lancet Glob Health 2020;8(1):e134-e42. doi: 10.1016/S2214-109X(19)30457-7.
4. Muriuki JM, Mentzer AJ, Webb EL, Morovat A, Kimita W, Ndungu FM, Macharia AW, Crane RJ, Berkley JA, Lule SA, et al. Estimating the burden of iron deficiency among African children. BMC Med 2020;18(1):31. doi: 10.1186/s12916-020-1502-7.
5. McCann JC, Ames BN. An overview of evidence for a causal relation between iron deficiency during development and deficits in cognitive or behavioral function. Am J Clin Nutr 2007;85(4):931-45. doi: 10.1093/ajcn/85.4.931.
6. Bacchetta J, Zaritsky JJ, Sea JL, Chun RF, Lisse TS, Zavala K, Nayak A, Wesseling-Perry K, Westerman M, Hollis BW, et al. Suppression of iron-regulatory hepcidin by vitamin D. J Am Soc Nephrol 2014;25(3):564-72. doi: 10.1681/ASN.2013040355.
7. Zughaier SM, Alvarez JA, Sloan JH, Konrad RJ, Tangpricha V. The role of vitamin D in regulating the iron-hepcidin-ferroportin axis in monocytes. J Clin Transl Endocrinol 2014;1(1):19-25. doi: 10.1016/j.jcte.2014.01.003.
8. Katsumata S, Katsumata R, Matsumoto N, Inoue H, Takahashi N, Uehara M. Iron deficiency decreases renal 25-hydroxyvitamin D3-1α-hydroxylase activity and bone formation in rats. BMC Nutrition 2016;2(1):1-7. doi: 10.1186/s40795-016-0072-8.
9. Braithwaite V, Prentice AM, Doherty C, Prentice A. FGF23 is correlated with iron status but not with inflammation and decreases after iron supplementation: a supplementation study. Int J Pediatr Endocrinol 2012;2012(1):27. doi: 10.1186/1687-9856-2012-27.
10. Braithwaite VS, Mwangi MN, Jones KS, Demir AY, Prentice A, Prentice AM, Andang'o PEA, Verhoef H. Antenatal iron supplementation, FGF23, and bone metabolism in Kenyan women and their offspring: secondary analysis of a randomized controlled trial. Am J Clin Nutr 2021;113(5):1104-14. doi: 10.1093/ajcn/nqaa417.
11. Schouten BJ, Hunt PJ, Livesey JH, Frampton CM, Soule SG. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab 2009;94(7):2332-7. doi: 10.1210/jc.2008-2396.
12. Perwad F, Zhang MY, Tenenhouse HS, Portale AA. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol 2007;293(5):F1577-83. doi: 10.1152/ajprenal.00463.2006.
13. Houghton LA, Brown RC, Beaumont S, Jennings S, Bailey KB, Haszard JJ, Erhardt J, Daniels L, Gibson RS. Micronutrient status differs among Maasai and Kamba preschoolers in a supplementary feeding programme in Kenya. Matern Child Nutr 2019;15(3):e12805. doi: 10.1111/mcn.12805.
14. Monlezun DJ, Camargo CA, Jr., Mullen JT, Quraishi SA. Vitamin D Status and the Risk of Anemia in Community-Dwelling Adults: Results from the National Health and Nutrition Examination Survey 2001-2006. Medicine (Baltimore) 2015;94(50):e1799. doi: 10.1097/MD.0000000000001799.

15. Lee JA, Hwang JS, Hwang IT, Kim DH, Seo JH, Lim JS. Low vitamin D levels are associated with both iron deficiency and anemia in children and adolescents. Pediatr Hematol Oncol 2015;32(2):99-108. doi: 10.3109/08880018.2014.983623.
16. Doudin A, Becker A, Rothenberger A, Meyer T. Relationship between serum 25-hydroxyvitamin D and red blood cell indices in German adolescents. Eur J Pediatr 2018;177(4):583-91. doi: 10.1007/s00431-018-3092-3.
17. Sharma S, Jain R, Dabla PK. The Role of 25-Hydroxy Vitamin D Deficiency in Iron Deficient Children of North India. Indian J Clin Biochem 2015;30(3):313-7. doi: 10.1007/s12291-014-0449-x.
18. Jin HJ, Lee JH, Kim MK. The prevalence of vitamin D deficiency in iron-deficient and normal children under the age of 24 months. Blood Res 2013;48(1):40-5. doi: 10.5045/br.2013.48.1.40.
19. Bejon P, Williams TN, Liljander A, Noor AM, Wambua J, Ogada E, Olotu A, Osier FH, Hay SI, Farnert A, et al. Stable and unstable malaria hotspots in longitudinal cohort studies in Kenya. PLoS Med 2010;7(7):e1000304. doi: 10.1371/journal.pmed.1000304.
20. Elliott AM, Kizza M, Quigley MA, Ndibazza J, Nampijja M, Muhangi L, Morison L, Namujju PB, Muwanga M, Kabatereine N, et al. The impact of helminths on the response to immunization and on the incidence of infection and disease in childhood in Uganda: design of a randomized, double-blind, placebo-controlled, factorial trial of deworming interventions delivered in pregnancy and early childhood [ISRCTN32849447]. Clin Trials 2007;4(1):42-57. doi: 10.1177/1740774506075248.
21. Tiono AB, Nebie I, Anagnostou N, Coulibaly AS, Bowyer G, Lam E, Bougouma EC, Ouedraogo A, Yaro JBB, Barry A, et al. First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children. PLoS One 2018;13(12):e0208328. doi: 10.1371/journal.pone.0208328.
22. Atkinson SH, Rockett K, Sirugo G, Bejon PA, Fulford A, O'Connell MA, Bailey R, Kwiatkowski DP, Prentice AM. Seasonal Childhood Anaemia in West Africa Is Associated with the Haptoglobin 2-2 Genotype. PLoS Med 2006;3(5):e172. doi: 10.1371/journal.pmed.0030172.
23. Nunes MC, Cutland CL, Jones S, Hugo A, Madimabe R, Simões EAF, Weinberg A, Madhi SA. Duration of Infant Protection Against Influenza Illness Conferred by Maternal Immunization. JAMA Pediatrics 2016;170(9):840-7. doi: 10.1001/jamapediatrics.2016.0921.
24. Mogire RM, Morovat A, Muriuki JM, Mentzer AJ, Webb EL, Kimita W, Ndungu FM, Macharia AW, Cutland CL, Sirima SB, et al. Prevalence and predictors of vitamin D deficiency in young African children. BMC Med 2021;19(1):1-14. doi: 10.1186/s12916-021-01985-8.
25. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM, Endocrine S. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96(7):1911-30. doi: 10.1210/jc.2011-0385.
26. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011;96(1):53-8. doi: 10.1210/jc.2010-2704.
27. WHO, CDC. Assessing the iron status of populations: report of a Joint World Health Organization/Centers for Disease Control and Prevention Technical Consultation on the Assessment of Iron Status at the Population Level, Geneva, Switzerland, 6-8 April

2004. Assessing the iron status of populations: report of a Joint World Health Organization/Centers for Disease Control and Prevention Technical Consultation on the Assessment of Iron Status at the Population Level, Geneva, Switzerland, 6-8 April 2004: World Health Organization and

Centers for Disease Control, 2005.

28. World Health Organization. WHO guideline on use of ferritin concentrations to assess iron status in individuals and populations. 2020.

29. Yamanishi H, Iyama S, Yamaguchi Y, Kanakura Y, Iwatani Y. Total iron-binding capacity calculated from serum transferrin concentration or serum iron concentration and unsaturated iron-binding capacity. Clin Chem 2003;49(1):175-8. doi: 10.1373/49.1.175.

30. World Health Organization. Iron Deficiency Anaemia: Assessment, Prevention, and Control. A Guide for Programme Managers. 2001. Geneva: World Health Organization 2001.

31. World Health Organization. WHO Child Growth Standards based on length/height, weight and age. Acta Paediatr Suppl 2006;450:76-85. doi: 10.1111/j.1651-2227.2006.tb02378.x.

32. Suh YJ, Lee JE, Lee DH, Yi HG, Lee MH, Kim CS, Nah JW, Kim SK. Prevalence and Relationships of Iron Deficiency Anemia with Blood Cadmium and Vitamin D Levels in Korean Women. J Korean Med Sci 2016;31(1):25-32. doi: 10.3346/jkms.2016.31.1.25.

33. Malczewska-Lenczowska J, Sitkowski D, Surala O, Orysiak J, Szczepanska B, Witek K. The Association between Iron and Vitamin D Status in Female Elite Athletes. Nutrients 2018;10(2):167. doi: 10.3390/nu10020167.

34. Judistiani RTD, Madjid TH, Irianti S, Natalia YA, Indrati AR, Ghozali M, Sribudiani Y, Yuniati T, Abdulah R, Setiabudiawan B. Association of first trimester maternal vitamin D, ferritin and hemoglobin level with third trimester fetal biometry: result from cohort study on vitamin D status and its impact during pregnancy and childhood in Indonesia. BMC Pregnancy Childbirth 2019;19(1):112. doi: 10.1186/s12884-019-2263-1.

35. Sato H, Takai C, Kazama JJ, Wakamatsu A, Hasegawa E, Kobayashi D, Kondo N, Nakatsue T, Abe A, Ito S, et al. Serum hepcidin level, iron metabolism and osteoporosis in patients with rheumatoid arthritis. Sci Rep 2020;10(1):9882. doi: 10.1038/s41598-020-66945-3.

36. Syed S, Michalski ES, Tangpricha V, Chesdachai S, Kumar A, Prince J, Ziegler TR, Suchdev PS, Kugathasan S. Vitamin D Status Is Associated with Hepcidin and Hemoglobin Concentrations in Children with Inflammatory Bowel Disease. Inflamm Bowel Dis 2017;23(9):1650-8. doi: 10.1097/MIB.0000000000001178.

37. Kulling PM, Olson KC, Olson TL, Feith DJ, Loughran TP, Jr. Vitamin D in hematological disorders and malignancies. Eur J Haematol 2017;98(3):187-97. doi: 10.1111/ejh.12818.

38. Atkinson SH, Armitage AE, Khandwala S, Mwangi TW, Uyoga S, Bejon PA, Williams TN, Prentice AM, Drakesmith H. Combinatorial effects of malaria season, iron deficiency, and inflammation determine plasma hepcidin concentration in African children. Blood 2014;123(21):3221-9. doi: 10.1182/blood-2013-10-533000.

39. Masoud MS, Yakout SM, Al-Attas OS, Alokail MS, Al-Daghri NM. The association between iron and vitamin D status in Arab adolescents. Public Health Nutr 2020;23(7):1208-13. doi: 10.1017/S1368980019001113.

40. Masoud MS, Alokail MS, Yakout SM, Khattak MNK, AlRehaili MM, Wani K, Al-Daghri NM. Vitamin D Supplementation Modestly Reduces Serum Iron Indices of Healthy Arab Adolescents. Nutrients 2018;10(12):1870. doi: 10.3390/nu10121870.

41. Camaschella C. Iron-deficiency anemia. N Engl J Med 2015;372(19):1832-43. doi: 10.1056/NEJMra1401038.

42. Smith EM, Tangpricha V. Vitamin D and anemia: insights into an emerging association. Curr Opin Endocrinol Diabetes Obes 2015;22(6):432-8. doi: 10.1097/MED.0000000000000199.

43. Liu T, Zhong S, Liu L, Liu S, Li X, Zhou T, Zhang J. Vitamin D deficiency and the risk of anemia: A meta-analysis of observational studies. Ren Fail 2015;37(6):929--34. doi: 10.3109/0886022X.2015.1052979.

44. Kalach N, Benhamou PH, Campeotto F, Dupont C. Anemia impairs small intestinal absorption measured by intestinal permeability in children. Eur Ann Allergy Clin Immunol 2007;39(1):20-2.

45. Heldenberg D, Tenenbaum G, Weisman Y. Effect of iron on serum 25-hydroxyvitamin D and 24,25-dihydroxyvitamin D concentrations. Am J Clin Nutr 1992;56(3):533-6. doi: 10.1093/ajcn/56.3.533.

46. Blanco-Rojo R, Perez-Granados AM, Toxqui L, Zazo P, de la Piedra C, Vaquero MP. Relationship between vitamin D deficiency, bone remodelling and iron status in iron-deficient young women consuming an iron-fortified food. Eur J Nutr 2013;52(2):695-703. doi: 10.1007/s00394-012-0375-8.

47. Sim JJ, Lac PT, Liu IL, Meguerditchian SO, Kumar VA, Kujubu DA, Rasgon SA. Vitamin D deficiency and anemia: a cross-sectional study. Ann Hematol 2010;89(5):447-52. doi: 10.1007/s00277-009-0850-3.

48. Clinkenbeard EL, Farrow EG, Summers LJ, Cass TA, Roberts JL, Bayt CA, Lahm T, Albrecht M, Allen MR, Peacock M, et al. Neonatal iron deficiency causes abnormal phosphate metabolism by elevating FGF23 in normal and ADHR mice. J Bone Miner Res 2014;29(2):361-9. doi: 10.1002/jbmr.2049.

Table 1. Characteristics of study participants

Participant characteristics	Overall	Kenya	Uganda	Burkina Faso	The Gambia	South Africa[8]
Total participants, n/total (%)	4509	1361/4509 (30.2%)	1301/4509 (28.9%)	329/4509 (7.3%)	629/4509 (13.9%)	889/4509 (22.9%)
Median age in months (IQR)	23.9 (12.3, 35.9)	19.8 (12.7, 36.8)	24.0 (23.9, 35.9)	23.4 (19.7, 26.4)	46.6 (35.2, 58.7)	12.0 (11.9, 12.1)
Females, n/total (%)	2216/4509 (49.1%)	671/1361 (49.3%)	641/1301 (49.3%)	161/329 (48.9%)	297/629 (47.2%)	446/889 (50.2%)
Malaria parasitaemia[1], n/total (%)	445/3293 (13.5%)	227/1082 (20.8%)	89/1280 (6.9%)	64/303 (21.1%)	65/628 (10.4%)	n/a
Inflammation[2], n/total (%)	1019/4469 (22.8%)	363/1344 (27.0%)	306/1285 (23.8%)	109/322 (33.9%)	85/629 (13.5%)	156/889 (17.6%)
Stunting, n/total (%)[3]	581/2289 (25.4%)	99/208 (47.6%)	203/1282 (15.8%)	103/307 (33.5%)	176/492 (35.8%)	n/a
Underweight, n/total (%)[4]	389/2487 (15.6%)	102/389 (26.2%)	103/1296 (8.0%)	58/309 (18.8%)	126/493 (25.6%)	n/a
Vitamin D status						
Median 25(OH)D (nmol/L)	77.0 (76.3, 77.7)	81.9 (80.4, 83.3)	78.3 (77.0, 79.5)	77.3 (75.0, 79.6)	70.4 (69.0, 71.9)	72.8 (71.2, 74.5)
25(OH)D >75 nmol/l	2485/4509 (55.1%)	815/1361 (59.9%)	756/1301 (58.1%)	186/329 (56.5%)	265/629 (42.1%)	463/889 (52.1%)
25(OH)D 50–75 nmol/l	1674/4509 (37.1%)	464/1361 (34.1%)	479/1301 (36.8%)	123/329 (37.4%)	302/629 (48.0%)	306/889 (34.4%)
25(OH)D <50 nmol/l	350/4509 (7.8%)	82/1361 (6.0%)	66/1301 (5.1%)	20/329 (6.1%)	62/629 (9.9%)	120/889 (13.5%)
25(OH)D <30 nmol/l	28/4509 (0.6%)	4/1361 (0.3%)	5/1301 (0.4%)	0 (0%)	2/629 (0.3%)	17/889 (1.9%)
Iron status						
Iron deficiency[5], n/total (%)	1546/4399 (35.1%)	491/1322 (37.1%)	433/1240 (34.9%)	115/319 (36.1%)	134/629 (21.3%)	373/889 (42.0%)
Iron deficiency anemia[6], n/total (%)	661/2880 (23.0%)	207/771 (26.9%)	209/1182 (17.7%)	96/304 (31.6%)	107/623 (17.2%)	n/a
Anemia[7], n/total (%)	1829/2971 (61.6%)	556/793 (70.1%)	623/1241 (50.2%)	274/314 (87.3%)	376/623 (62.4%)	n/a
Biomarker medians (IQR)						
Ferritin (µg/L)	20.5 (10.4, 39.5)	21.4 (10.2, 46.4)	20.8 (10.0, 40.6)	20.9 (10.2, 45.1)	25.7 (15.3, 42.3)	16.6 (9.1, 27.9)
Hepcidin (µg/L)	7.2 (2.7, 16.1)	6.2 (2.2, 14.3)	7.2 (3.0, 15.9)	5.8 (2.2, 14.3)	7.9 (2.8, 16.6)	8.7 (3.7, 18.8)
sTfR (mg/L)	11.3 (6.0, 16.8)	17.2 (13.7, 22.7)	7.0 (4.7, 10.0)	17.3 (12.8, 24.7)	3.2 (2.7, 4.2)	11.3 (8.9, 13.8)
Transferrin (µg/L)	2.8 (2.4, 3.1)	2.8 (2.4, 3.2)	2.7 (2.4, 3.1)	2.7 (2.4, 3.1)	n/a	2.8 (2.4, 3.1)
Iron (µmol/L)	7.0 (4.8, 10.5)	6.7 (4.6, 9.8)	n/a	6.1 (4.2, 8.7)	8.7 (6.1, 12.3)	n/a
TSAT (%)	10.4 (6.7, 16.2)	9.4 (6.2, 14.8)	n/a	9.2 (5.9, 14.1)	13.2 (8.6, 19.4)	n/a
Hemoglobin (g/dL)	10.6 (9.6, 11.5)	10.4 (9.4, 11.2)	11.0 (10.1, 11.9)	9.7 (8.9, 10.5)	10.8 (9.9, 11.5)	n/a

25(OH)D, 25-hydroxyvitamin D; IQR, interquartile range; n/a, not available; CRP, C-reactive protein; sTfR, soluble transferrin receptors; TSAT, transferrin saturation. [1]Malaria parasitaemia was defined as presence of *Plasmodium* parasitaemia on blood film; [2]inflammation as CRP > 5 mg/L or ACT >0.6 g/L (ACT, but not CRP was available for The Gambia); [3]stunting as height-for-age Z score <-2 and [4]underweight as weight-for-age Z score < -2; [5]iron deficiency as either plasma ferritin <12µg/L or <30µg/L in the presence of inflammation in children <5 years old, or <15µg/L or <70µg/L in the presence of inflammation in children ≥5 years old; [6]iron deficiency anemia as the presence of both iron deficiency and anemia; [7]anemia as hemoglobin <11 g/dL in children aged <5 years, or hemoglobin <11.5 g/dL in children ≥5 years. [8]Anthropometric and hemoglobin measurements were not available for the South African children and they were not

exposed to malaria.

Table 2. Effects of vitamin D status on iron deficiency, iron deficiency anemia and anemia

		Vitamin D status categories based on 25(OH)D levels						
		>75 nmol/L (reference)	**50–75 nmol/L**			**<50 nmol/L**		
Proportion, n/total (%)		2485/4509 (55.1%)	1674/4509 (37.1%)			350/4509 (7.8%)		
		n	**n**	**OR (95% CI)**	**p**	**n**	**OR (95% CI)**	**p**
Iron deficiency[1]	Overall	2425/4399	1632/4399	1.11 (0.97, 1.28)	0.14	342/4399	1.80 (1.40, 2.31)	<0.0001
	Kenya	794/1322	450/1322	0.86 (0.65, 1.13)	0.27	78/1322	0.94 (0.53, 1.67)	0.84
	Uganda	725/1240	452/1240	0.95 (0.73, 1.23)	0.68	63/1240	1.84 (1.07, 3.15)	0.027
	Burkina Faso	178/319	122/319	1.12 (0.66, 1.90)	0.67	19/319	0.95 (0.31, 2.89)	0.93
	The Gambia	265/629	302/629	0.82 (0.54, 1.24)	0.35	62/629	1.06 (0.53, 2.13)	0.86
	South Africa	463/889	306/889	2.45 (1.78, 3.37)	<0.0001	120/889	4.80 (3.07, 7.52)	<0.0001
Iron deficiency anemia[2]	Overall	1540/2880	1139/2880	0.93 (0.77, 1.14)	0.51	201/2880	1.41 (0.97, 2.07)	0.075
	Kenya	420/771	293/771	0.91 (0.61, 1.38)	0.68	58/771	0.96 (0.41, 2.26)	0.93
	Uganda	690/1182	430//1182	0.91 (0.67, 1.25)	0.57	62//1182	1.85 (1.00, 3.45)	0.052
	Burkina Faso	167/304	118/304	1.01 (0.57, 1.76)	0.98	19/304	0.77 (0.24, 2.53)	0.67
	The Gambia	263/623	298/623	0.98 (0.62, 1.57)	0.96	62/623	1.66 (0.81, 3.42)	0.17
	South Africa	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Anemia[3]	Overall	1587/2971	1175/2971	1.00 (0.84, 1.18)	0.98	209/2971	1.30 (0.94, 1.80)	0.11
	Kenya	430/793	301/793	0.65 (0.45, 0.93)	0.019	65/793	0.71 (0.38, 1.32)	0.28
	Uganda	719/1241	457/1241	1.08 (0.84, 1.39)	0.55	65/1241	1.08 (0.62, 1.87)	0.79
	Burkina Faso	175/314	119/314	1.37 (0.65, 2.88)	0.41	20/314	2.14 (0.26, 17.66)	0.48
	The Gambia	263/623	298/623	1.35 (0.96, 1.91)	0.086	62/623	2.75 (1.45, 5.17)	0.002
	South Africa	n/a	n/a	n/a	–	n/a	n/a	–

25(OH)D, 25-hydroxyvitamin D; n/a, not available. Odds ratios and p values were obtained from multivariable logistic regression analyses adjusted for age, sex, season, inflammation and study site. 25(OH)D and CRP levels were ln-transformed to make them normally distributed. [1]Iron deficiency was defined as either plasma ferritin <12µg/L or <30µg/L in the presence of inflammation in children <5 years old, or <15µg/L or <70µg/L in the presence of inflammation in children ≥5 years old; [2]iron deficiency anemia as the presence of both iron deficiency and anemia; [3]anemia was defined as hemoglobin <11 g/dL in children aged <5 years, or hemoglobin <11.5 g/dL in children ≥5 years; inflammation as CRP > 5 mg/L or ACT >0.6 g/L (ACT, but not CRP was available for The Gambia).

i. Prevalence of iron status by categories vitamin D status

ii. Prevalence of vitamin D status by categories iron status

A. Ferritin
β = 0.19
R2 = 0.003
P <0.0001

B. Hepcidin
β = 0.048
R2 <0.0001
P = 0.44

C. sTfR
β = 0.24
R2 = 0.012
P <0.0001

D. Transferrin
β = 0.48
R2 = 0.068
P <0.0001

E. Iron
β = -0.31
R2 = 0.024
P <0.0001

G. Hemoglobin
β = -0.37
R2 = 0.006
P <0.0001

F. TSAT
β = -0.44
R2 = 0.038
P <0.0001

H. CRP
β = 0.66
R2 = 0.016
P <0.0001